Document is current
Any future updates will be listed below
-
Authors
Rood, Julia E. https://orcid.org/0000-0002-0755-8897
Yoon, Suh Kyung https://orcid.org/0009-0009-6258-6119
Heard, Mary K.
Carro, Stephen D.
Hedgepeth, Emma J. https://orcid.org/0009-0005-8767-6402
O’Mara, Mary E.
Hogan, Michael J. https://orcid.org/0000-0002-6244-2993
Le, Nhu
Muramatsu, Hiromi https://orcid.org/0000-0003-1544-1493
Lam, Kieu https://orcid.org/0000-0002-1965-5491
Schreiner, Petra https://orcid.org/0000-0001-8952-4748
Kasden, Coral https://orcid.org/0000-0003-3320-5099
Stedman, Hansell H. https://orcid.org/0000-0003-2700-1815
Langlois, Ryan A.
Heyes, James https://orcid.org/0000-0001-9499-2028
Pardi, Norbert https://orcid.org/0000-0003-1008-6242
Eisenlohr, Laurence C. https://orcid.org/0000-0002-8475-7910
- License Information
-
More Information
Article History
Received: 27 August 2025
Accepted: 16 December 2025
First Online: 16 January 2026
Competing interests
: J.H., K.L., and P.S. are employees of Genevant Sciences Corporation (GSC), as noted in the author affiliations, and own shares or options in the company. N.P. served on the mRNA strategic advisory board of Sanofi Pasteur in 2022, Pfizer in 2023-2024, and AldexChem between 2023 and 2025. N.P. is a member of the Scientific Advisory Board of BioNet and Piezo Therapeutics and has consulted for Vaccine Company Inc. and Pasture Bio. M.J.H. has consulted on mRNA vaccines for YourBio Health and Paul Hastings LLP. The other authors declare no competing interests.
